These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28737225)

  • 1. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
    Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychostimulant effect of levodopa: reversing sensitisation is possible.
    Castrioto A; Kistner A; Klinger H; Lhommée E; Schmitt E; Fraix V; Chabardès S; Mertens P; Quesada JL; Broussolle E; Pollak P; Thobois SC; Krack P
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):18-22. PubMed ID: 22991345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Biundo R; Weis L; Abbruzzese G; Calandra-Buonaura G; Cortelli P; Jori MC; Lopiano L; Marconi R; Matinella A; Morgante F; Nicoletti A; Tamburini T; Tinazzi M; Zappia M; Vorovenci RJ; Antonini A
    Mov Disord; 2017 Nov; 32(11):1557-1565. PubMed ID: 28960475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
    Béreau M; Fleury V; Bouthour W; Castrioto A; Lhommée E; Krack P
    Rev Neurol (Paris); 2018 Nov; 174(9):653-663. PubMed ID: 30224159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
    Cenci MA
    Trends Neurosci; 2007 May; 30(5):236-43. PubMed ID: 17400300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?
    Ambermoon P; Carter A; Hall W; Dissanayaka N; O'Sullivan J
    Addiction; 2012 Feb; 107(2):241-7. PubMed ID: 21793971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.
    Stevenson JK; Talebifard P; Ty E; Oishi MM; McKeown MJ
    Exp Brain Res; 2011 Oct; 214(3):471-9. PubMed ID: 21877102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.
    Martínez-Fernández R; Schmitt E; Martinez-Martin P; Krack P
    Mov Disord; 2016 Aug; 31(8):1080-94. PubMed ID: 27431515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.
    Ghadery C; Valli M; Mihaescu A; Strafella R; Navalpotro I; Kim J; Strafella AP
    Int Rev Neurobiol; 2018; 141():365-404. PubMed ID: 30314604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa addiction in idiopathic Parkinson disease.
    Borek LL; Friedman JH
    Neurology; 2005 Nov; 65(9):1508. PubMed ID: 16275855
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    LeWitt PA; Hauser RA; Grosset DG; Stocchi F; Saint-Hilaire MH; Ellenbogen A; Leinonen M; Hampson NB; DeFeo-Fraulini T; Freed MI; Kieburtz KD
    Mov Disord; 2016 Sep; 31(9):1356-65. PubMed ID: 27090868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personality, addiction, dopamine: insights from Parkinson's disease.
    Dagher A; Robbins TW
    Neuron; 2009 Feb; 61(4):502-10. PubMed ID: 19249271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.